Premium
Cobalt‐57 bleomycin for imaging head and neck tumors
Author(s) -
Woolfenden James M.,
Alberts David S.,
Hall Jack N.,
Patton Dennis D.
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197905)43:5<1652::aid-cncr2820430514>3.0.co;2-i
Subject(s) - medicine , bleomycin , head and neck cancer , head and neck , cobalt , radiology , nuclear medicine , surgery , radiation therapy , chemotherapy , inorganic chemistry , chemistry
Cobalt‐57 bleomycin imaging was performed in 11 patients with a history of head and neck cancer. Clinical and scan findings concurred on the presence and extent of tumor in 9 patients (82%); tumor was present in 7 and absent in 2 of the 9. In 2 patients (18%) the scan demonstrated tumor in the neck but failed to show metastatic sites. Cobalt‐57 bleomycin images were of good technical quality, with remarkably low background activity at 24 hours after administration. Cobalt‐57 bleomycin imaging appears to be a promising technique for evaluating patients with head and neck tumors.